📊 #ReigJofre grows 10% in revenues and 13% in EBITDA, highlighting the increase in profitability. 📈 In the first half of 2024, we reached €173 million in revenues, and EBITDA of €20.1 million. Our operating profit also improved by 30% to €7.7 million, thanks to our focus on more profitable products and markets. 🌍 Although the international business now accounts for 56% of our revenues, with growth of 13%, it is essential to highlight that our growth comes from various levers within the business itself. High demand for antibiotics, advancement in dermatology, the growth of Forté Pharma, and our expertise in advanced technology are fundamental to our profit. 🔧 In addition, we have invested €8.9 million to upgrade our plants in Toledo and Barcelona, thus strengthening our production and technological capabilities. Discover all the details in the press release 👉 https://lnkd.in/dRJnsyYC — 📊 #ReigJofre crece un 10% en ingresos y un 13% en EBITDA, destacando el aumento de la rentabilidad 📈 En el primer semestre de 2024, hemos alcanzado 173 millones de euros en ingresos, y un EBITDA de 20,1 millones de euros. Nuestro resultado de explotación también ha crecido un 30%, situándose en 7,7 millones de euros, gracias a nuestro enfoque en productos y mercados más rentables. 🌍 Aunque el negocio internacional ahora representa el 56% de nuestros ingresos, con un crecimiento del 13%, es esencial destacar que nuestro crecimiento proviene de diversas palancas dentro del propio negocio. La alta demanda de antibióticos, el avance en dermatología, el crecimiento de Forté Pharma, y nuestra nuestra experiencia en tecnología avanzada son fundamentales para nuestro beneficio. 🔧 Además, hemos invertido 8,9 millones de euros para mejorar nuestras plantas en Toledo y Barcelona, fortaleciendo así nuestras capacidades productivas y tecnológicas. Descubre todos los detalles en la nota de prensa 👉 https://lnkd.in/dmgxhP3n
Reig Jofre’s Post
More Relevant Posts
-
#Dermal #Fillers #Market Industry Share, Top Key Players, Regional Study forecast 2029 𝐆𝐞𝐭 𝐚 𝐝𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬..!!https://lnkd.in/d8FKaFv8 📈 Market Dynamics: R&D investments by industry players have #yielded advanced products with enhanced aesthetic #outcomes, fostering market expansion. Moreover, the growing acceptance of #minimally invasive procedures among diverse demographic groups, including men, promises to unlock new growth avenues. 🌍 Regional Insights: North America dominates the #market, driven by a tech-savvy populace and a high #demand for cosmetic treatments. Europe follows suit, witnessing significant growth propelled by rising R&D spending and increasing demand in key nations like Germany. #Meanwhile, Asia Pacific emerges as a promising market, fueled by burgeoning beauty consciousness and expanding healthcare infrastructure. 🔍 Segment Analysis: Hyaluronic acid remains the #industry standard, while biodegradable fillers dominate the #market due to their safety and regulatory approvals. Scar treatment and wrinkle correction #emerge as primary application segments, while specialty & dermatology clinics lead in end-user preferences. Key Players : Allergan REVANCE THERAPEUTICS LTD Merz Pharma Dessau Galderma Sculpt Lab Prollenium Medical Technologies Inc. DermalFillers #CosmeticEnhancements #MarketInsights #BeautyIndustry #Aesthetics #GlobalMarket #Innovation #COVID19Impact #Healthcare #MarketTrends
To view or add a comment, sign in
-
-
🟢#INVESTIGACIÓN | LEO Pharma lanzará un nuevo tratamiento para el eccema crónico en España La farmacéutica danesa LEO Pharma está próxima a obtener la aprobación para el #lanzamiento de la crema #Delgocitinib, la primera dirigida a pacientes con eccema crónico de manos moderado a grave. Además, la empresa planea seguir creciendo en #España. Juan Fran Cuello de Oro Rozas, director general de LEO Pharma para #Iberia, indicó que la siguiente etapa consiste en obtener la #aprobación de la #EMA y, posteriormente, la Comisión Europea para su #comercialización. "Esperamos recibir la #aprobación CE para 2024", afirmó Cuello de Oro, destacando que cada país europeo tendrá sus propios procesos de acceso al mercado. El #ensayo clínico #DeltaForce, que comparó #delgocitinib con #alitretinoína en cápsulas, mostró que la nueva crema logró una mayor #reducción en la gravedad del eccema a las doce semanas. Además, delgocitinib superó a alitretinoína en todos los #objetivos secundarios clave. LEO Pharma prevé seguir expandiendo su #negocio en el mercado ibérico, en línea con sus #resultados de 2023. En 2023, la #compañía aumentó sus #ingresos un 6,9% en la región y prevé continuar con esta #tendencia de #crecimiento en 2024. En 2025, LEO Pharma cumplirá treinta años en el mercado español. Continúa leyendo👉 Haz clic en el #enlace del primer comentario 👇 #leopharma #delgocitinib #eccema #dermatología #tratamientofarmacéutico #salud #bienestar #investigación #innovación #aprobaciónCE #mercadoibérico #dermatitis
To view or add a comment, sign in
-
-
Spine Biologics Market Size And Forecast Spine Biologics Market size is expected to develop revenue and exponential market growth at a remarkable CAGR during the forecast period from 2024–2031. The comprehensive report of the Spine Biologics Market will analyse data changes and their impact on the market at the global level. It also analyses the overall growth of companies in the market and their abilities to manage and control profit levels, which is highly important to any investor wishing to open and expand a company within the same market. ➢𝐓𝐨𝐩 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐦𝐞𝐧𝐭𝐢𝐨𝐧𝐞𝐝 𝐚𝐬 𝐛𝐞𝐥𝐨𝐰: ➢ ➢ Orthofix ➢ LifeNet Health ➢ Metric Bio ➢ Isto Biologics ➢ MCRA ➢ Accelus ➢ Spinal Elements ➢ Precision Spine ➢ Skye Biologics, Inc. ➢ Innovasis, Inc. ➢ Kuros Biosciences ➢ Amendia ➢ SpineSmith ➢ Fuse Medical ➢ Medical Metrics, Inc. ➢ Global Regenerative Academy Inc. ➢ Medyssey USA ➢ Bacterin International, Inc. ➢ Viscogliosi Bros., LLC ➢ Biologica Technologies ➢ Fair Winds Medical ➢ Spineart USA ➢ AEONSurgical ➢ Allgens Medical, Inc. ➢ Fox Valley Orthopedics ➢ Orthopedic Specialists Palm Harbor FL ➢ GBV Medical Solutions ➢ Orthofix International NV ➢ Fair Winds Medical ➢ Spineart USA ➢ AEONSurgical ➢ Allgens Medical, Inc. ➢ Fox Valley Orthopedics ➢ Orthopedic Specialists Palm Harbor FL ➢ GBV Medical Solutions ➢ Orthofix International NV ➢ Sales Questions Brutally Honest Answers - PodCast #data #sales #marketresearch #research #entrepreneur #businessstrategy #technology #data #sales #datacollection #salesfunnel #contentmarketing #bhfyp #size #forecast # #Share #Scope #Opportunities #Analysis #SpineBiologicsMarket
To view or add a comment, sign in
-
-
🚀 Digital & Business Transformation 🎯 Driving Success for Pharma & Healthcare through New Strategies & Business Models, Commercial Innovation and Organizational Transformation | Former J&J-Novo Nordisk executive
🔥 Johnson & Johnson comprará PROTEOLOGIX Inc por 850 millones de dólares ✔ PROTEOLOGIX Inc es una empresa especializada en el desarrollo de anticuerpos para el tratamiento de la dermatitis atópica y el asma. La biotech dispone ya de dos anticuerpos en desarrollo. ✔ La farmacéutica estadounidense quiere incorporar, con esta adquisición, nuevos tratamientos contra la dermatitis atópica, conocida comúnmente como eccema, y el asma. ✔ Recientemente, Johnson & Johnson también ha suscrito un acuerdo para la adquisición de Shockwave Medical, ampliando así su presencia en el segmento de intervención cardiovascular y acelerando su transición hacia mercados de mayor crecimiento. La adquisición de Shockwave Medical sigue a las compras por parte de Johnson & Johnson MedTech de Abiomed, especialista en recuperación cardíaca, y más recientemente de Laminar, Inc.. https://lnkd.in/dDmzQU7v #estrategia #jnj #innovacion #farmaceuticas #pharma #biotech #dermatologia #respiratorio #medtech #cardiologia
To view or add a comment, sign in
-
🔸 𝗔𝗰𝘁𝘂𝗮𝗹𝗶𝗱𝗮𝗱 | Emylif, la innovadora formulación de riluzol en película bucodispersable para pacientes con ELA, disponible en España👇🏼 https://lnkd.in/d2BtQMgh -- 📌 Si quieres formar parte de la mayor comunidad de la Industria Farmacéutica, estás a un clic https://lnkd.in/d9gZk6g4 #farmaleaderstalento #industriafarmaceutica #pharma #research #clinicalresearch #farmacia #dispositivosmédicos #investigación #medicina #biotecnologia #healthcare #regulatoryaffairs #healthcare #hospital #medicamentos #cancer
Emylif, la innovadora formulación de riluzol en película bucodispersable para pacientes con ELA, disponible en España
pmfarma.com
To view or add a comment, sign in
-
Another major news from Rubedo Life Sciences our portfolio company, they’ve just announced a move into skincare and cosmetics. Rubedo entered a multi-year strategic partnership with German multinational beauty company Beiersdorf AG to develop innovative skin care products that address the effects of cellular aging. Notably, Beiersdorf additionally joins Rubedo as a strategic investor, having participated in its recent Series A financing. Yesterday I wrote that LongeVC is also a part of this $40 million round, led by Khosla Ventures and Ahren Innovation Capital. The collaboration focuses on the development of novel compounds with senolytic and anti-inflammatory properties from Rubedo's topical dermatology program. To address cellular senescence, which is linked to age-related skin alterations and diseases. Beiersdorf will perform in vitro and in silico studies. They will evaluate Rubedo's compounds, leading to in vivo human trials to confirm their effectiveness in cosmetic skin care products. As part of the agreement, Rubedo will receive milestone payments and royalties from Beiersdorf. As I mentioned in the previous post, Rubedo’s “superpower” is their AI-driven discovery platform ALEMBIC™ and their unique expertise and focus on cellular senescence. #agingresearch #senescence #longevity #drugdiscovery image from pr:
To view or add a comment, sign in
-
-
15k followers / PhD & Dr.h.c. / Certified #AI enthusiast / International pharma business expert / Speaker / Polyglot / Devoted dad.
¿Cuáles fueron los 10 proveedores ganadores con mayor crecimiento en piezas de abril a mayo 2024 en el segmento de medicamentos? #SanofiPasteur , #Proquigama, #Solara, #SagoMedical , #Pentamed, #Nucitec, #PharmaManagementAndInnovation, #MedicaFarmaArcar, #Amarox, #AdministradoraDeMarcasFarmacéuticas Los principales grupos terapéuticos en los que estas empresas están garantizando los inventarios y las existencias necesarias para beneficio de la población derechohabiente son: Reumatología y Traumatología, Enfermedades Infecciosas y Parasitarias, Nutriología, Nefrología y Urología, Enfermedades Inmunoalérgicas, Psiquiatría, Neurología, Analgesia, Oncología, Soluciones Electrolíticas y Sustitutos del Plasma, Intoxicaciones. Información procesada con los INEFAM #AlphaDogs
To view or add a comment, sign in
-
-
Comprehensive Insights into the 𝐖𝐨𝐮𝐧𝐝 𝐂𝐚𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭: Trends, Size, and Future Growth 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐚𝐭 https://lnkd.in/dq_KvejY The global wound care market in terms of revenue was estimated to be worth $21.5 billion in 2023 and is poised to reach $28.6 billion by 2028, growing at a CAGR of 5.9% from 2023 to 2028. Recent Developments of Wound Care Industry - In January 2023, Convatec Group (UK) launched ConvaFoam, which can be used on a spectrum of wound types at any stage of the wound journey, making it the simple dressing choice for wound management and skin protection. - n September 2022, MiMedx Group, Inc. (US) launched of AMNIOEFFECT, a tri-layer PURION processed human tissue allograft consisting of the amnion, intermediate, and chorion membrane layers of the placenta. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: 3Mcompany Cardinal Health Medtronic Smith & Nephew, Inc. Mölnlycke Health Care Mölnlycke Health Care US B. Braun Group Baxter International Inc. Convatec Group Convatec India PAUL HARTMANN Ges.m.b.H. PAUL HARTMANN Hellas Coloplast Organogenesis MiMedx Group Integra LifeSciences Bioventus Zimmer Biomet Ethicon, Inc. Deroyal Industries Kerecis ACell, Inc. Lohmann & Rauscher Lohmann & Rauscher UK Medela TALLEY GROUP LIMITED Welcare Industries S.p.A. Wuhan VSD Medical Science & Technology Co., Ltd. Pensar Medical™ HAROMED - medical technologies DermaRite Industries Medline Industries, LP Advancis Medical MIL LABORATORIES PRIVATE LIMITED #woundcare #woundcaremarket #woundcaresize
To view or add a comment, sign in
-
-
Spine Biologics Market Size And Forecast Spine Biologics Market size is expected to develop revenue and exponential market growth at a remarkable CAGR during the forecast period from 2024–2031. The comprehensive report of the Spine Biologics Market will analyse data changes and their impact on the market at the global level. It also analyses the overall growth of companies in the market and their abilities to manage and control profit levels, which is highly important to any investor wishing to open and expand a company within the same market. ➢𝐓𝐨𝐩 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐦𝐞𝐧𝐭𝐢𝐨𝐧𝐞𝐝 𝐚𝐬 𝐛𝐞𝐥𝐨𝐰: ➢ ➢ Orthofix ➢ LifeNet Health ➢ Metric Bio ➢ Isto Biologics ➢ MCRA ➢ Accelus ➢ Spinal Elements ➢ Precision Spine ➢ Skye Biologics, Inc. ➢ Innovasis, Inc.➢ Kuros Biosciences ➢ Amendia ➢ SpineSmith ➢ Fuse Medical ➢ Medical Metrics, Inc. ➢ Global Regenerative Academy Inc. ➢ Medyssey USA ➢ Bacterin International, Inc. ➢ Viscogliosi Bros., LLC ➢ Biologica Technologies➢ Fair Winds Medical ➢ Spineart USA ➢ AEONSurgical ➢ Allgens Medical, Inc. ➢ Fox Valley Orthopedics ➢ Orthopedic Specialists Palm Harbor FL ➢ GBV Medical Solutions ➢ Orthofix International NV➢ Fair Winds Medical ➢ Spineart USA ➢ AEONSurgical ➢ Allgens Medical, Inc. ➢ Fox Valley Orthopedics ➢ Orthopedic Specialists Palm Harbor FL ➢ GBV Medical Solutions ➢ Orthofix International NV ➢ Sales Questions Brutally Honest Answers - PodCast #data #sales #marketresearch #research #entrepreneur #businessstrategy #technology #data #sales #datacollection #salesfunnel #contentmarketing #bhfyp #size #forecast # #Share #Scope #Opportunities #Analysis #SpineBiologicsMarket
To view or add a comment, sign in
-